Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00187707
Status:
COMPLETED
Last Update Posted:
2012-08-09
First Post:
2005-09-14
Brief Title:
Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters Previously we have recruited a cohort of healthy volunteers Studies of Pharmacogenetics in Ethnically-diverse Populations or SOPHIE and have resequenced the coding region of a number of membrane transporter genes to identify genetic polymorphisms in these genes We plan to take a genotype-to-phenotype approach to study the influence of specific polymorphisms in the intestinal transporters such as the novel organic cation transporters 1 and 2 OCTN1 and OCTN2 genes on the bioavailability of gabapentin in healthy subjects Eligible subjects will have a single inpatient study visit during which they will take a single dose of gabapentin and provide blood and urine samples over the course of 36 hours 5 terminal elimination gabapentin half-lives for pharmacokinetic analysis
Detailed Description:
Detailed description pending
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None